AOA Dx is a cutting-edge startup that operates in the healthcare technology sector, specifically focusing on early cancer detection. The company has developed GlycoLocate™, an Artificial Intelligence (AI) enabled platform that leverages the power of data science to detect cancer at its earliest stages. This innovative technology is the first of its kind to utilize tumor marker gangliosides, a new class of biomarkers, to provide unprecedented insights into early cancer detection.

The company primarily serves healthcare providers and patients, with a particular emphasis on women's health. AOA Dx's business model revolves around the research, development, and commercialization of its proprietary technology. The company generates revenue by licensing its technology to healthcare providers and institutions, who then use it to enhance their diagnostic capabilities and patient care.

AOA Dx is a team of seasoned industry experts and entrepreneurs who are dedicated to bringing impactful and cost-effective medical technologies to the market. The company is committed to innovation in women's health and is at the forefront of pioneering the field of glycolipids.

Keywords: AOA Dx, GlycoLocate™, early cancer detection, AI-enabled platform, data science, tumor marker gangliosides, biomarkers, women's health, healthcare technology, glycolipids.